Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 1 Baseline characteristics of the hepatitis B virus-DNA > 2000 and hepatitis B virus-DNA ≤ 2000 groups, n (%)

Variable	Group		P value
	HBV-DNA > 2000, n = 54	HBV-DNA ≤ 2000, n = 66
HBV			0.614
Negative	37 (69)	48 (73)
Positive	17 (31)	18 (27)
Antiviral therapy			0.068
No	8 (15)	19 (29)
Yes	46 (85)	47 (71)
Child Pugh score			0.724
A	22 (41)	29 (44)
B	32 (59)	37 (56)
IVPTT			0.595
No	26 (48)	35 (53)
Yes	28 (52)	31 (47)
BCLC stage			0.776
B	21 (39)	24 (36)
C	33 (61)	42 (64)
Metastasis			0.632
No	31 (57)	35 (53)
Yes	23 (43)	31 (47)
AFP			0.271
> 1210	24 (44)	36 (55)
≤ 1210	30 (56)	30 (45)
Sex			0.925
Female	20 (37)	25 (38)
Male	34 (63)	41 (62)
Age			0.811
< 60	29 (54)	34 (52)
≥ 60	25 (46)	32 (48)
BMI			0.413
Low	36 (67)	37 (56)
Normal	2 (4)	6 (9)
Obese	1 (2)	4 (6)
Overweight	15 (28)	19 (29)
ECOG			0.271
0-1	29 (54)	42 (64)
2	25 (46)	24 (36)
Post operative			0.549
No	34 (63)	38 (58)
Yes	20 (37)	28 (42)
ALT			0.083
> 40	29 (54)	25 (38)
≤ 40	25 (46)	41 (62)
Total bilirubin			0.969
> 34	37 (69)	45 (68)
≤ 34	17 (31)	21 (32)
Diabetes			0.832
No	41 (76)	49 (74)
Yes	13 (24)	17 (26)
Hypertensive			0.920
No	16 (30)	19 (29)
Yes	38 (70)	47 (71)
Cirrhosis			0.753
No	31 (57)	36 (55)
Yes	23 (43)	30 (45)
Smoking			0.889
No	37 (69)	46 (70)
Yes	17 (31)	20 (30)
Alcohol			0.893
No	35 (65)	42 (64)
Yes	19 (35)	24 (36)
Virus reactivation			1.000
No	53 (98)	65 (98)
Yes	1 (1.9)	1 (1.5)

Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; PVTT: Portal vein tumor thrombosis.